ETON position history
The shares of Eton Pharmaceuticals (ETON) that Opaleye Management Inc. reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 3,088,100 shares, $16M, 2.9% of portfolio
- 2021 Q4: 2,385,000 shares, $10M, 2.2% of portfolio, Reduce −22.8%
- 2022 Q1: 2,379,275 shares, $10M, 3.2% of portfolio, Reduce −0.2%
- 2022 Q2: 2,462,500 shares, $6.5M, 2.9% of portfolio, Add +3.5%
- 2022 Q3: 2,521,000 shares, $5.3M, 2.2% of portfolio, Add +2.4%
- 2022 Q4: 2,170,000 shares, $6.1M, 2.1% of portfolio, Reduce −13.9%
- 2023 Q1: 2,185,000 shares, $8.4M, 2.5% of portfolio, Add +0.7%
- 2023 Q2: 2,285,000 shares, $8M, 1.9% of portfolio, Add +4.6%
- 2023 Q3: 2,430,270 shares, $10M, 3.3% of portfolio, Add +6.4%
- 2023 Q4: 2,529,887 shares, $11M, 2.9% of portfolio, Add +4.1%
- 2024 Q1: 4,891,562 shares, $18M, 4.1% of portfolio, Add +93.4%
- 2024 Q2: 2,395,000 shares, $7.9M, 1.8% of portfolio, Reduce −51.0%
- 2024 Q3: 2,780,000 shares, $17M, 2.8% of portfolio, Add +16.1%
- 2024 Q4: 2,852,070 shares, $38M, 6.6% of portfolio, Add +2.6%
- 2025 Q1: 2,852,070 shares, $37M, 8.2% of portfolio
- 2025 Q2: 5,720,000 shares, $82M, 16.4% of portfolio, Add +100.6%
- 2025 Q3: 2,860,000 shares, $62M, 8.8% of portfolio, Reduce −50.0%
- 2025 Q4: 5,720,000 shares, $97M, 12.8% of portfolio, Add +100.0%
- 2026 Q1: 2,860,000 shares, $71M, 9.3% of portfolio, Reduce −50.0%
- 2026 Q2: 2,860,000 shares, $104M, 9.4% of portfolio
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|